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Therapeutics in alopecia areata (AA) have remained re-
latively unchanged for many years, with few treatments
having more than moderate e¡ects in severely a¡ected
patients. The advent of the new biologic medications
in the dermatologic world, however, particularly in
psoriasis treatment, introduces possibilities of treatment
for many other immune-mediated diseases. Keywords:
biologic response modi¢ers/psoriasis/alopecia areata. JID
Symposium Proceedings 8:217 ^218, 2003
A
lopecia areata is one possible candidate disease for
biologic modi¢er application. It is an autoimmune
form of hair loss that can cause patchy or complete
loss of hair anywhere on the body, though most
patients experience this loss on the scalp. AA is
mediated byT cells, with a primarilyTH1 cytokine pro¢le in ac-
tive disease. This TH1 pro¢le is a shared characteristic in AA and
psoriasis, suggesting that any drug that can target T cells safely
and decrease activity in the skin may work for both diseases. So
far, the new biologic immunomodulating drugs are an exciting
new development for the treatment of psoriasis and associated ar-
thritis. In this short report, the new drugs, called biologic re-
sponse modi¢ers, will be evaluated in terms of mechanism,
e⁄cacy, and safety. Their possible application in AA warrants a
full discussion of their practical considerations and points of ther-
apeutic attack.
PSORIASIS
Psoriasis is a chronic, life-altering, in£ammatory skin disease that
exhibits erythematous, scaling plaques. It is known to be immune
mediated, which leads to an overproduction of keratinocytes.The
disease a¡ects more than 2% of the population, and approxi-
mately 2 million Americans have moderate to severe involve-
ment. There are complex therapeutic options for psoriasis, many
of which attack the immune-mediated portion of the disease as
opposed to keratinocyte overproduction.
In dermatology, psoriasis is a prototypic T cell^mediated dis-
ease (Bos and Rie, 1999; Nickolo¡, 1999). Abundant evidence of
itsTcell^mediated nature comes from bone marrow experiments,
where psoriasis has developed in the recipient of bone marrow
from a psoriasis-a¡ected patient. It is also well known that the
cells in psoriasis are CD8 and CD4 lymphocytes withTH1 cyto-
kine phenotype, as well as IL-2, IFN-g and TNF-a. Finally, the
role of T cells is clear in psoriasis when the disease improves sig-
ni¢cantly with drugs that target proliferative T cells, such as
methotrexate. Because of this prototype, psoriasis has been the
main target of the new biologic treatments, but it is likely only
the ¢rst of many dermatologic diseases that will ultimately enter
clinical trials for these agents.
THE BIOLOGIC RESPONSE MODIFIERS
The new biologic agents are protein drugs produced in vitro
through recombinant DNA techniques. They include recombi-
nant cytokines, humanized monoclonal antibodies, and molecu-
lar receptors that bind target molecules. When the biologic
response modi¢ers were considered in the treatment of psoriasis,
the treatment strategies included moderating or eliminatingTcell
e¡ects. Four major strategies have been described: targeting
pathogenicTcells, inhibitingTcell activation or migration, indu-
cing immune deviation, and inhibiting postsecretory cytokines
(Singri et al, 2002). The four drugs furthest along in clinical trials
for psoriasis are alefacept, efalizumab, in£iximab, and etarnercept.
Each has a varying pro¢le of bene¢ts that can, and likely will, be
applied to other dermatologic diseases in the future.
Alefacept Alefacept (Amevive, Biogen Inc., Cambridge, MA)
is a human fusion protein that can be intravenously or
intramuscularly administered. Pivotal clinical trials are complete,
and the drug was aproved by the FDA in January 2003 for the
treatment of adult patients with moderate to severe chronic
plaque psoriasis who are candidates for systemic therapy or
phototherapy. The drug became available for use in February
2003.
Alefacept was designed to bind CD2, inhibit antigen^
presenting cell interaction with T cells, and selectively reduce
CD45R0þ cells. Mean percent change in psoriasis from the
Baseline Psoriasis Area and Severity Index (PASI) has been
signi¢cant for this drug after even one dose, and continued
improvement is observed weeks after a second dose.1 Safety
must be considered before deciding to begin trials with a
drug in psoriasisa nonfatal, albeit very symptomatic and
psychologically damaging disease. Alefacept is known to kill
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activated memoryT cells, reversibly lowering T cell count. There
appears to be no increase in infection rate in subjects taking the
medication, nor are there any infusion reactions. Also important
is that there is no detectable e¡ect on response to new or old
antigen challenge. CD4þ T lymphocytes must be monitored
weekly during the 12-week dosing period and used to guide
dosing.
Adverse events commonly observed in the ¢rst course of
placebo-controlled clinical trials with at least 2% or higher
incidence in patients treated with alefaceft compared to those
treated with placebo include pharyngitis, dizziness, increased
cough, nausea, pruritus, myalgia, chills, injection site pain, and
injection site in£ammation. The acquisition price of alefacept
will range from $7000 to $10,000 per 12-week course depending
on dosing. The drug must be administered in a physician’s o⁄ce,
as either an intravenous or a subcutaneous injection.
Treatment of AAwith alefacept may be a reasonable option if
e⁄cacy can be demonstrated in clinical trials, but the weekly
in-o⁄ce dosing may make administration cumbersome. Cost
is comparative with other biologic drugs and will require
preapproval by insurance carriers for most patients.
Efalizumab Efalizumab (Raptiva, Genentech, Inc., and
XOMA, Ltd., Berkley, CA) is an anti-CD11a molecule that
works via several mechanisms as a subcutaneous injection. The
¢rst mechanism is inhibition of interaction between T cells and
antigen-presenting cells; the second is inhibition of T cell
migration from blood. In psoriasis, disease development depends
upon the e¡ective rolling of T cells along the endothelium, their
binding, and then their migration into the skin. Efalizumab
appears to lessen the T cell’s immune functions (Gottlieb et al,
2002). Its e⁄cacy is demonstrated with 75% improvement
in PASI in 30% of subjects in one study and an increase in
improvement with increased use. There were no serious
infections or injection reactions seen in clinical trial subjects.
There was also no reported rebound with continued use,
although there is a potential rebound if the drug is abruptly
discontinued. Phase III pivotal trials evaluating moderate-to-
severe psoriasis have been completed, and a Biologic Licensce
Application has been ¢led with the FDA for efalizumab use
in adult moderate-to-severe chronic plaque psoriasis as a once-
weekly subcutaneous injection. Like alefecept, efalizumab
showed no problems with challenge of new antigens. The drug
has been used in trials as a once-weekly subcutaneous injection.
The safety and administration pro¢le of efalizumab may make
it ideal for clinical trials in AA. At-home injection of the drug
would be preferred by most patients with AA, as would the lack
of blood monitoring.
TNF-a Inhibitors The next two agents are both TNF-a
inhibitors. Etanercept and in£iximab are already on the market,
but neither is approved for the treatment of psoriasis or for any
other dermatologic condition.
In£iximab (Remicaide, Centocor, Inc.) is an intravenous anti-
TNF antibody that kills cells having surface TNF. It is approved
for Crohn’s disease and rheumatoid arthritis. Signi¢cant improve-
ment in mean PASI score can be seen in as few as ten weeks of
in£iximab treatment (Chaudhari et al, 2001). Associated with this
drug are serious infusion reactions, rare reported cases of pancy-
topenia, rare activation of tuberculosis and other granulomatous
infections, rare lymphomas, multiple sclerosis, and positive ANA
titers thought to be related to the destruction of soluble and ¢xed
TNF on their surface (cells presumably needed for full immune
function against granulomatous infection). Problems with poten-
tial use of in£iximab in an AA population include the aforemen-
tioned side e¡ects and the inconvenience of an intravenous
administration.
Etanercept (Enbrel, Amgen, Inc.) is a soluble TNF receptor that
works by binding circulation TNF. It is approved for the treat-
ment of psoriatic arthritis and adult and juvenile rheumatoid ar-
thritis. In psoriasis, 75% improvement is seen after etanercept
treatment for 24 weeks. There are signi¢cant data available on
the toxicities of etanercept because the drug has been approved
for so long for the above indications. In controlled trials, injection
site reactions were reported in 37% of patients; infection of any
kind was reported in 52.6% (versus 36.4% of placebo patients) in
current indications.2 In the current indications, treatment with
etanercept is not indicated in patients with active infection. Also,
caution must be exercised when using this drug in patients who
have congestive heart failure.2,3 The pharmaco-viligence of eta-
nercept is the most extensive of all the major biologic drugs. Sur-
veillance includes spontaneous safety reports, long-term trials of
safety in North America and Europe, the European Safety Reg-
istry, and the Juvenile Rheumatoid Arthritis Safety Registry.This
agent is administered subcutaneously twice weekly when dosed
to treat the approved medical indications. It may show promise
for the treatment of AA with favorable at-home administration
and long-term safety data.
SUMMARY
The biologic response modi¢ers are novel agents that are de-
signed to attack one speci¢c part of the immunologic process of
psoriasis, much as could be done in the treatment of AA. Their
speci¢city lessens the likelihood of severe and unwanted side ef-
fects at the same time allowing the immune system to function in
a normal way. Drug^drug interactions can be avoided, as can sig-
ni¢cant organ toxicity, with these agents.
The likelihood that more biologic drugs will be designed and
tested further in psoriasis underscores the need to investigate the
full spectrum of their application.When other diseases are consid-
ered for treatment with the new biologics, it is important to
weigh the likelihood of improvement of the disease and the pos-
sibility of serious side e¡ects, as well as drug availability to the
average insured patient. There is no doubt that the biologics have
not been designed speci¢cally for the treatment of AA; however,
there are lessons to be learned from this new arena for all derma-
tologists interested in treating immune-mediated diseases.
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